MedTrace Logo

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

NCT07459647 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2026-04-22

No results posted yet for this study

Summary

ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

Conditions

Interventions

DRUG

ML-007C-MA

ML-007C-MA dosed as 210/3 mg BID

Sponsors & Collaborators

  • MapLight Therapeutics

    lead INDUSTRY

Principal Investigators

  • MapLight Therapeutics · MapLight Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2030-02-28
Completion
2030-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07459647 on ClinicalTrials.gov